Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.65 |
| ▸ | CLK1 | P49759 | 2/20 | 0.65 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.65 |
| ▸ | CLK2 | P49760 | 1/20 | 0.65 |
| ▸ | CLK3 | P49761 | 1/20 | 0.65 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.65 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.65 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.65 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.65 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.65 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.65 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.51 |
| ▸ | PIM1 | P11309 | 3/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | PAK4 | O96013 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | TRPA1 | O75762 | 8/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.47 |
| ▸ | NOS1 | P29475 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11295 | 0.87 | FGFR1 (0.65) | GSK3BCLK1DYRK3CLK2CLK3 | |
| SCHEMBL182465 | 0.86 | NOS1 (0.53) | GSK3BCLK1DYRK3CLK2CLK3 | |
| SCHEMBL29569257 | 0.86 | NOS1 (0.53) | GSK3BCLK1DYRK3CLK2CLK3 | |
| SCHEMBL12633807 | 0.80 | NOS1 (0.44) | GSK3BCLK1DYRK3CLK2CLK3 | |
| SCHEMBL2455100 | 0.79 | GSK3B (1.00) | GSK3BCLK1DYRK3CLK2CLK3 | |
| SCHEMBL16740690 | 0.77 | NOS1 (0.72) | GSK3BCLK1DYRK3CLK2CLK3 | |
| SCHEMBL27663173 | 0.77 | FGFR1 (0.74) | GSK3BCLK1DYRK3CLK2CLK3 | |
| SCHEMBL4791316 | 0.77 | CLK1 (1.00) | GSK3BCLK1DYRK3CLK2CLK3 | |
| SCHEMBL16573980 | 0.77 | GSK3B (0.71) | GSK3BCLK1DYRK3CLK2CLK3 | |
| SCHEMBL23063810 | 0.75 | GSK3B (0.68) | GSK3BCLK1DYRK3CLK2CLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230052747-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS | TES PHARMA S.R.L. (IT) | 2023-02-16 | — | — | US | disclosed |
| US-20230052747-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS | TES PHARMA S.R.L. (IT) | 2023-02-16 | — | — | US | disclosed |
| WO-2021116999-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2021-06-17 | — | — | WO | disclosed |
| US-20120295915-A1 | AZABENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2012-11-22 | — | — | US | disclosed |
| EP-2503890-A1 | AZABENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GlaxoSmithKline LLC (US) | 2012-10-03 | — | — | EP | disclosed |
| EP-2493310-A1 | BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GlaxoSmithKline LLC (US) | 2012-09-05 | — | — | EP | disclosed |
| US-20120208827-A1 | BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2012-08-16 | — | — | US | disclosed |
| US-20120208827-A1 | BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2012-08-16 | — | — | US | disclosed |
| WO-2011066211-A1 | AZABENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-06-03 | — | — | WO | disclosed |
| WO-2011056635-A1 | BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011056635-A1 | BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208827-A1 | BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | GSK3B 1796/4885CLK1 2884/4885DYRK3 4262/4885 |
| US-20120295915-A1 | AZABENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, COASY | GSK3B 2222/4885CLK1 4716/4885DYRK3 3348/4885 |
| US-20230052747-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS | RAD51, BRCA1, FANCI | GSK3B 970/4885CLK1 2750/4885DYRK3 3626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.